BMO Capital Downgrades OncoMed Pharmaceuticals (OMED) to Market Perform
Tweet Send to a Friend
BMO Capital downgraded OncoMed Pharmaceuticals (NASDAQ: OMED) from Outperform to Market Perform with a price target of $6.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
